PeptidePros
All Peptides

PEG-MGF

Also known as Pegylated MGF · PEGylated Mechano Growth Factor

PEGylated MGF with no identified human exposure data per FDA. Extreme platform risk.

Tier Dextreme riskadvancedWADA S2FDA Flagged
Tier D
Evidence
Protocol
extreme
Risk
subcut.
Route

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

Extreme Risk

This substance is in the extreme platform risk category due to growth-factor signaling, mitogenic potential, or complete absence of human safety data. Exercise maximum caution.

No Human Data

No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.

Evidence visual

PEG-MGF evidence and risk matrix

advanced researcher fit

Evidence

Tier D

Risk

extreme

Regulatory

not approved

WADA

S2

FDA

flagged

Route

subcutaneous

Weak evidence profile. Treat claims conservatively and compare better-supported alternatives first.

Overview

PEG-MGF is a pegylated version of Mechano Growth Factor. FDA reports it has not identified any human exposure data for PEG-MGF drug products and flags immunogenicity/characterization complexity. If PEGylated, characterization of PEG conjugation distribution and impurity profile is required — not just 'purity %.' This is an extreme uncertainty and compliance risk item.

Decision path

Where PEG-MGF fits in the research path.

Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.

1 related goal
  1. 01

    Read evidence

  2. 02

    Check risk

  3. 03

    Compare options

  4. 04

    Build plan

Peptide research path

Decide whether PEG-MGF belongs in your plan.

Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.

Research Details

Mechanism of Action

PEGylated MGF designed for prolonged activity; mechanism relates to IGF-1 splice variant muscle repair signaling.

Administration Routes

subcutaneous

Study Dose Range

No identified human exposure data per FDA.

Expected Effects

Proposed prolonged muscle repair signaling; claims largely unverified.

Dosing Timeline

Unknown in humans.

Contraindications

No data; extreme uncertainty.

Adverse Effects

FDA flags immunogenicity/characterization complexity; no human exposure data identified.

Interaction Notes

Unknown.

Cost at a glance

No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.

Known Interactions

Avoid

IGF-1 LR3

High-risk IGF/MGF clustering; insufficient safety basis for consumer routing; FDA flags PEG-MGF compounding risks and no identified human exposure data.

Avoid

Follistatin

Growth-factor cluster; insufficient safety basis for consumer routing.

Caution

FOXO4-DRI

High uncertainty + growth-factor cluster.

Frequently Compared

Compare top

CJC-1295

Tier B

Ipamorelin

Tier B-C

GHRP-2

Tier B

GHRP-6

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Personalized peptide routing

Find the right path for PEG-MGF.

Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.

  • Goal-matched compound and protocol recommendations.
  • Budget and sourcing filters before you leave the site.
  • PDF unlocks shown after your personalized result.
Take the quiz